Abstract:Purpose: 18F-Florzolotau is a novel second-generation tau radiotracer that shows higher binding affinity and selectivity and no off-target binding. The proportion loss of functional connectivity strength (PLFCS) is a new indicator for representing brain functional connectivity (FC) alteration. This study aims to estimate the relationship between the regional tau accumulation and brain FC abnormality in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients based on Florzolotau PET and fMRI. Methods: 22 NC (normal control), 31 MCI and 42 AD patients who have already been scanned with 18F-Florzolotau PET were recruited in this study. (We calculated the PLFCS and standardized uptake value ratio (SUVR) of each node based on the Brainnetome atlas (BNA) template. The SUVR of 246 brain regions was calculated with the cerebellum as the reference region. Further functional connection strength (FCs), PLFCS and SUVR of each brain region were obtained in three groups for comparison.) For each patient, PLFCS and standardized uptake value ratio (SUVR) were calculated based on the Brainnetome atlas (BNA) template. These results, as well as functional connection strength (FCs), were then compared between different groups. Multiple permutation tests were used to determine the target nodes between NC and cognitive impairment (CI) groups (MCI and AD). The relationship between PLFCS and neuropsychological scores or cortical tau deposit was investigated via Pearson correlation analysis. Results: Higher PLFCS and FCs in AD and MCI groups were found compared to the NC group. The PLFCS of 129 brain regions were found to be different between NC and CI groups, and 8 of them were correlated with tau SUVR, including superior parietal lobule (MCI: r = 0.4360, p = 0.0260, AD: r = −0.3663, p = 0.0280), middle frontal gyrus (AD: MFG_R_7_2: r = 0.4106, p = 0.0129; MFG_R_7_5: r = 0.4239, p = 0.0100), inferior frontal gyrus (AD: IFG_R_6_2: r = 0.3589, p = 0.0316), precentral gyrus (AD: PrG_R_6_6: r = 0.3493, p = 0.0368), insular gyrus (AD: INS_R_6_3: r = 0.3496, p = 0.0366) and lateral occipital cortex (AD: LOcC _L_4_3: r = −0.3433, p = 0.0404). Noteworthily, the opposing relationship was found in the superior parietal lobule in the MCI and AD groups. Conclusions: Brain functional connectivity abnormality is correlated with tau pathology in AD and MCI.

In Vivo 18 F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia.

In Vivo F-18-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

In Vivo <scp><sup>18</sup>F‐Florzolotau</scp> Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies

18F-Florzolotau Tau Positron Emission Tomography Imaging in Patients with Multiple System Atrophy-Parkinsonian Subtype

International Consensus on the Use of Tau PET Imaging Agent 18F-Flortaucipir in Alzheimer's Disease.

<SUP>18</SUP>F-Florzolotau Positron Emission Tomography Imaging of Tau Pathology in the Living Brains of Patients with Corticobasal Syndrome

Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis

18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

In Vivo18F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

In Vivo 18 F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

In Vivo Tau Burden is Associated with Abnormal Brain Functional Connectivity in Alzheimer’s Disease: A 18F-Florzolotau Study

A~(18)F-fluorodeoxyglucose (FDG)/PET Study of Advanced Parkinson's Disease

Feasibility of 18F-Florzolotau Quantification in Patients with Alzheimer's Disease Based on an MRI-free Tau PET Template

Direct Comparison between 18 F-Flortaucipir tau PET and Quantitative Susceptibility Mapping in Progressive Supranuclear Palsy

18F-MK6240 PET imaging of tau protein in Alzheimer′s disease and cognitive correlation analysis

[ 18 F]-PM-PBB3-PET Tau Imaging in Alzheimer’s Dementia and PSP

The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease

Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation.

In vivo PET imaging of neuroinflammation in familial frontotemporal dementia

A Peculiar Tau Accumulation Pattern Identified Via 18 F-Florzolotau PET Imaging in a Patient With Frontotemporal Dementia Caused by a Mutation in the MAPT Gene